ATE145335T1 - Kreuzreaktive immunisierung gegen influenza - Google Patents

Kreuzreaktive immunisierung gegen influenza

Info

Publication number
ATE145335T1
ATE145335T1 AT91915798T AT91915798T ATE145335T1 AT E145335 T1 ATE145335 T1 AT E145335T1 AT 91915798 T AT91915798 T AT 91915798T AT 91915798 T AT91915798 T AT 91915798T AT E145335 T1 ATE145335 T1 AT E145335T1
Authority
AT
Austria
Prior art keywords
cross
against influenza
immunization against
virus
reactive immunization
Prior art date
Application number
AT91915798T
Other languages
English (en)
Inventor
Francis A Ennis
Original Assignee
Univ Massachusetts Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts Medical filed Critical Univ Massachusetts Medical
Application granted granted Critical
Publication of ATE145335T1 publication Critical patent/ATE145335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91915798T 1990-08-08 1991-08-07 Kreuzreaktive immunisierung gegen influenza ATE145335T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56471490A 1990-08-08 1990-08-08

Publications (1)

Publication Number Publication Date
ATE145335T1 true ATE145335T1 (de) 1996-12-15

Family

ID=24255587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915798T ATE145335T1 (de) 1990-08-08 1991-08-07 Kreuzreaktive immunisierung gegen influenza

Country Status (9)

Country Link
EP (2) EP0711564A1 (de)
AT (1) ATE145335T1 (de)
AU (1) AU8501191A (de)
CA (1) CA2090005C (de)
DE (1) DE69123252T2 (de)
DK (1) DK0542895T3 (de)
ES (1) ES2094233T3 (de)
GR (1) GR3021983T3 (de)
WO (1) WO1992002250A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766601A (en) * 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
WO1994022917A1 (en) * 1993-04-05 1994-10-13 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (es) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider

Also Published As

Publication number Publication date
DE69123252D1 (de) 1997-01-02
GR3021983T3 (en) 1997-03-31
WO1992002250A1 (en) 1992-02-20
EP0542895B1 (de) 1996-11-20
EP0711564A1 (de) 1996-05-15
EP0542895A1 (de) 1993-05-26
DK0542895T3 (da) 1997-05-12
AU8501191A (en) 1992-03-02
ES2094233T3 (es) 1997-01-16
CA2090005A1 (en) 1992-02-09
DE69123252T2 (de) 1997-03-13
CA2090005C (en) 2003-10-28

Similar Documents

Publication Publication Date Title
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
ATE127345T1 (de) Stressproteine und verwendungen dafür.
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
ES2092306T3 (es) Adyuvante para vacunas.
EP0330359A3 (de) Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
TR199801722T2 (xx) Peptit imm�nojenler.
DE69331495D1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
NL300186I1 (nl) Acellulair vaccin.
DK0588578T3 (da) Immunogener
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
ATE157258T1 (de) Zubereitungen und behandlungen von pneumonia in tieren
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
DK204588D0 (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
NO980721L (no) Vaksiner

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee